Elbion NV was formed by the merger of elbion AG and 4AZA Bioscience. Elbion’s mission is to discover and develop new small molecule drugs for CNS diseases and immunological. Elbion has a maturing pipeline with three clinical products in areas of significant commercial potential, and a further portfolio of high quality late preclinical development compounds. The company’s principle products are Naltrexone Depot, ELB245, ELB353, PDE10, elbHCV and Buprenorphine Depot.